"In one month, the six patients, all suffering from acute respiratory distress syndrome received I.V. infusions of 150 million allogeneic cardiosphere-derived cells. Of the five who were on ventilators, four no longer needed them within one to four days following the infusion, the company said. The fifth remains on mechanical ventilation, and the sixth patient is receiving supplemental oxygen and is listed as clinically stable. Four of the six have been discharged from Cedars-Sinai.
Laboratory biomarkers correlated with poor outcomes were measured in all six patients. Following the infusion, several patients showed improvements in biomarkers such as ferritin, absolute lymphocyte counts and C-reactive protein. No adverse events related to the administration of CAP-1002 were observed.
Capricor said CAP-1002’s immune-modulatory properties could be at the center of reining in an overstimulated immune system by modulating various inflammatory cytokines and regulating the immune response. It’s possible that the body’s overreaction to COVID-19, rather than the virus itself, can lead to death, the company added."
News 
Market Data 
Discover 
